AstraZeneca (LON:AZN) Shares Pass Above Two Hundred Day Moving Average - Here's Why

Key Points

• AstraZeneca's stock price recently crossed above its 200-day moving average, indicating potential bullish trend, with current trading around £119.63 ($161.73).
• Analysts maintain a consensus rating of "Moderate Buy" for AstraZeneca, with target prices ranging from GBX 110 to £140.
• Insider selling activity was noted, with Aradhana Sarin selling 9,563 shares for approximately £1.1 million at an average price of £115.12.

AstraZeneca PLC (LON:AZN - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £109.18 ($147.20) and traded as high as £121.26 ($163.49). AstraZeneca shares last traded at £119.63 ($161.29), with a volume of 1,000,986 shares changing hands.

Analysts Set New Price Targets

AZN has been the topic of several research reports. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a £110 target price on shares of AstraZeneca in a research report on Wednesday, July 30th. Shore Capital reiterated a "buy" rating and set a £135 price objective on shares of AstraZeneca in a research report on Tuesday, July 29th. Finally, Berenberg Bank reiterated a "buy" rating and set a GBX 140 price objective on shares of AstraZeneca in a research report on Friday, May 16th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, AstraZeneca has an average rating of "Moderate Buy" and a consensus price target of GBX 9,660.

AstraZeneca Stock Performance

The firm has a 50 day simple moving average of £108.53 and a 200-day simple moving average of £109.20. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The company has a market cap of £228.50 billion, a price-to-earnings ratio of 32.55, a PEG ratio of 0.86 and a beta of 0.17.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Aradhana Sarin sold 9,563 shares of the firm's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of £115.12, for a total transaction of £1,100,892.56. 0.04% of the stock is currently owned by company insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.